Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arterra Bioscience SpAMIL:ARBS 80 EV-to-EBIT is 9.43 as of Sep. 22, 2026, which is 13% above its 10-year median of 8.36. GuruFocus rates MIL:ARBS with a GF Score™ of 80/100 and a GF Value™ of €2.94 (Fairly Valued). Among 381 Biotechnology companies, Arterra Bioscience SpA ranks better than 57.22% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Arterra Bioscience SpA's Enterprise Value for the quarter that ended in Dec. 2025 was €19.03 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Arterra Bioscience SpA's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €2.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:ARBS vs VRTX, REGN, MRNA: EV-to-EBIT Comparison
For the Biotechnology subindustry, Arterra Bioscience SpA's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arterra Bioscience SpA EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arterra Bioscience SpA's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Arterra Bioscience SpA's EV-to-EBIT falls into.
Arterra Bioscience SpA's current Enterprise Value is €18.85 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Arterra Bioscience SpA's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €2.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arterra Bioscience SpA (MIL:ARBS) has a EV-to-EBIT of 9.43 as of Sep. 22, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Arterra Bioscience SpA and its competitors. This is 13% above median its historical median of 8.36. Over the past decade, Arterra Bioscience SpA's EV-to-EBIT has ranged from 2.74 to 28.82. According to the industry distribution chart, Arterra Bioscience SpA ranks #163 out of 381 companies in the Biotechnology industry, placing it in the top 42.8%.
Is Arterra Bioscience SpA's EV-to-EBIT too high?
Arterra Bioscience SpA's current EV-to-EBIT of 9.43 is 13% above median its 10-year median of 8.36. Over the past 10 years, this metric has ranged from a low of 2.74 to a high of 28.82. The Biotechnology industry median EV-to-EBIT is 14.08. Arterra Bioscience SpA's value of 9.43 is 33% below this industry median. Based on the distribution chart, Arterra Bioscience SpA ranks #163 out of 381 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Arterra Bioscience SpA has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Arterra Bioscience SpA's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Arterra Bioscience SpA ranks #163 out of 381 companies for EV-to-EBIT. This puts Arterra Bioscience SpA in the upper half of its industry. The industry median EV-to-EBIT is 14.08. Arterra Bioscience SpA's value of 9.43 is 33% below this benchmark. Historically, Arterra Bioscience SpA's own EV-to-EBIT has ranged from 2.74 to 28.82 over the past decade. While the company's 10-year median is 8.36 vs. the industry median of 14.08, Arterra Bioscience SpA has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 14.08, based on 381 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arterra Bioscience SpA's current EV-to-EBIT of 9.43 is 33% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Arterra Bioscience SpA and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 14.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arterra Bioscience SpA's current EV-to-EBIT is 9.43, which is 13% above median its own 10-year median of 8.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arterra Bioscience SpA stock overvalued right now?
Based on GuruFocus' analysis, Arterra Bioscience SpA (MIL:ARBS) is currently considered Fairly Valued. The stock's GF Value™ is €2.94, compared to a current price of €3.10 — trading 5.4% above its estimated fair value. The current EV-to-EBIT is 9.43, which is 13% above median its 10-year median of 8.36 and 33% below the Biotechnology industry median of 14.08. Arterra Bioscience SpA's overall GF Score™ is 80/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Arterra Bioscience SpA (MIL:ARBS), the current EV-to-EBIT is 9.43 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arterra Bioscience SpA (MIL:ARBS) Overvalued in 2026?
Based on GuruFocus' analysis, Arterra Bioscience SpA stock appears to be overvalued.
The current stock price of €3.10 is trading 5.4% above its estimated GF Value™ of €2.94.
GuruFocus considers Arterra Bioscience SpA to be Fairly Valued.
Key valuation signals for MIL:ARBS:
EV-to-EBIT: 9.43 (13% above median its 10-year median of 8.36)
GF Value™: €2.94 vs. price of €3.10 (5.4% above fair value)
Industry Position: 33% below the Biotechnology median (#163 of 381)
No single metric tells the full story. See the MIL:ARBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arterra Bioscience SpA is a biotechnology company focused on the research and development of ingredients and natural solutions. It engages in the development of technological platforms, employed in the screening of active compounds for different industrial applications; setting up of new extraction processes, aimed at improving the sustainability and yield of interesting compounds; and production of high-tech raw materials with application in different industrial fields.
80GF Score
Get the complete analysis for MIL:ARBS
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:ARBS has been successfully added to your 
